Benefits
~3-4× improved boswellic acid bioavailability
Riva et al. 2016 randomized double-blind crossover pharmacokinetic study in 12 healthy volunteers comparing 500 mg Casperome vs 500 mg unformulated boswellia. Casperome produced markedly higher plasma levels of all major boswellic acids — particularly β-boswellic acids — reaching biologically active concentrations that unformulated boswellia could not at the same weight dose.
Full 11-boswellic acid spectrum
Standard boswellia products typically standardize to AKBA or KBA only. Casperome captures all 11 boswellic acids present in the natural Boswellia serrata resin (including BBA, AβBA, αBA, AαBA, KBA, AKBA). Some research suggests synergy among multiple boswellic acids — though direct head-to-head evidence vs AKBA-only extracts is limited.
Joint and exercise-induced inflammation
Multiple clinical investigations support Casperome for joint discomfort, including a rugby player knee injury trial showing significant improvements in pain-free walking distance and reduced inflammation markers vs standard care over 4 weeks. NSAID reduction documented in some participants.
IBS and gut inflammation applications
Indena reports three human studies supporting Casperome for gut health, particularly maintaining physiological intestinal motility and reducing bloating in functional GI conditions. Mechanism plausible given boswellic acids' anti-inflammatory effects in intestinal tissues.
Lower effective dose vs unformulated boswellia
Practical formulator advantage: 250-500 mg/day Casperome can replace 1-3 g of unformulated boswellia for similar plasma boswellic acid exposure. Allows smaller capsule sizes, multi-ingredient formulations, and better consumer compliance compared to large-volume traditional boswellia dosing.
Excellent safety in clinical use
No significant adverse events reported across the Casperome clinical study portfolio. Soy lecithin component generally safe but worth noting for patients with severe soy allergy. The phytosome complex itself doesn't alter the fundamental safety profile of boswellia.
Mechanism of action
Phytosome enhanced absorption
Phytosome® technology complexes lipophilic plant actives with phospholipids (soy lecithin), creating amphipathic structures that pass through the intestinal membrane more efficiently than the parent extract alone. Same platform used for Indena's other phytosomes (curcumin, milk thistle, ginkgo, green tea). Bioavailability gains typically 2-7× across the phytosome portfolio.
5-lipoxygenase (5-LO) inhibition
Once absorbed, Casperome's boswellic acids inhibit 5-LO and reduce leukotriene production — the core anti-inflammatory mechanism of all boswellia products. The phytosome doesn't change the mechanism, just the delivered dose at the site of action.
NF-κB and caspase modulation
Boswellic acids inhibit NF-κB transcription factor activation and caspase protein degradation pathways. These mechanisms drive inflammation across joint, gut, and respiratory tissues — explaining the multi-organ application profile.
mPGE2 synthase inhibition
Boswellic acids selectively inhibit microsomal prostaglandin E2 synthase (mPGE2S) — distinct from the COX-1/COX-2 targets of NSAIDs. This means boswellia reduces inflammatory PGE2 without inhibiting the gastroprotective PGE2 produced via COX-1, explaining its better GI safety vs NSAIDs.
Clinical trials
Randomized, double-blind, crossover pharmacokinetic study in 12 healthy volunteers comparing 500 mg Casperome vs 500 mg unformulated boswellia extract (single dose, washout between treatments).
Clinical population described in trial publication.
Randomized, double-blind, crossover pharmacokinetic study in 12 healthy volunteers comparing 500 mg Casperome vs 500 mg unformulated boswellia extract (single dose, washout between treatments). Casperome produced significantly higher plasma levels of all major boswellic acids — particularly β-boswellic acids reaching biologically relevant concentrations. First demonstration that a single 500 mg dose achieves meaningful plasma exposure in humans.
4-week trial in rugby players with knee injuries comparing Casperome + standard care vs standard care alone.
Clinical population described in trial publication.
4-week trial in rugby players with knee injuries comparing Casperome + standard care vs standard care alone. Casperome group showed pain-free walking distance approximately 3× greater than control, 22% greater reduction in inflammation markers, and approximately one-third of Casperome participants stopped NSAIDs entirely. Demonstrates exercise-recovery application beyond chronic OA.